金吾财讯 | 默沙东(MRK)周一表示,正就收购美国癌症和罕见疾病制药商SpringWorks Therapeutics(SWTX)进行深入谈判。据媒体当天早些时候援引三位消息人士称,如果谈判成功,可能会在未来几周签署协议。他们没有透露正在讨论的具体条款。总部位于康涅狄格州斯坦福的SpringWorks于2019年在纽约上市,是一家商业阶段的生物技术公司,开发用于治疗各种癌症的药物,包括罕见肿瘤和子宫癌。美国医疗保健行业的交易活动在2024年有所放缓后,目前正显示出回暖的迹象。强生公司上个月同意以约146亿美元收购Intra-Cellular Therapeutics。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.